BioCentury
ARTICLE | Clinical News

Microcyn Scar Management Hydrogel regulatory update

December 9, 2013 8:00 AM UTC

FDA granted 510(k) clearance to Oculus' Microcyn Scar Management HydroGel to manage old and new hypertrophic and keloid scarring from burns, general surgical procedures and trauma wounds. Quinnova Pharmaceuticals Inc. (Newton, Pa.) plans to launch the product 1H14. Quinnova has rights to Microcyn technology from Oculus under a 2011 deal (see BioCentury, Feb. 21, 2011). ...